Intas’ Response To Second Data Integrity Inspection Still Did Not Go Far Enough, US FDA Says
Executive Summary
Intas – the the troubled Indian firm at the center of the cisplatin shortage – may have punished workers for their visual-inspection subterfuge, but it also should have gone after managers, the FDA asserted in a second data integrity warning letter in four months.